Biogen obliterated Wall Street's first-quarter expectations Wednesday, helped by a nearly perfect sales beat sweep from its growth products.

Biogen (NASDAQ:BIIB) executives pointed to a “very strong start” to 2026, highlighting growth in key products, progress ...

This acquisition will add Syfovre and Empaveli to Biogen’s portfolio of medicines.

Biogen has entered into an agreement with TJ Biopharma (TJ Bio) to acquire exclusive rights to felzartamab in the Greater ...

Biogen has agreed to acquire Apellis Pharmaceuticals after an extended negotiation process. The company also entered a collaboration with Alloy Therapeutics focused on antisense drug development using ...

Following its move to secure ex-China rights to the CD38-directed antibody felzartamab, Biogen is doubling down and building ...

In April 2026, Biogen announced that it would acquire exclusive rights to TJ Biopharma’s felzartamab in Greater China for up to $850m.

With this transaction, Biogen now owns exclusive worldwide development and commercialization rights to felzartamab, consolidating global rights under one owner Advancing felzartamab – a CD38-directed ...

Biogen (BIIB) stock is in focus as the company beats forecasts with its Q1 2026 financials and trims its full-year earnings ...

On Apellis, "we have the proposed Apellis acquisition" and "we do expect the acquisition to be accretive in 2027" (CEO Viehbacher). "Total revenue was $2.5 billion" and "non-GAAP diluted EPS of $3.57" ...

Jefferies downgraded Biogen Inc (NASDAQ:BIIB), citing the company’s tough setup. Leqembi (lecanemab) sales growth remains sluggish, falling below consensus projections through 2030. Challenges like ...